Trial Outcomes & Findings for A Phase 2 Study of CIM331 for Atopic Dermatitis Patients (NCT NCT01986933)

NCT ID: NCT01986933

Last Updated: 2022-01-25

Results Overview

Percent changes from baseline in pruritus VAS at Week 12. VAS indicates pruritus intensity in the last 24 hours, from 0 (no itch) to 10 (worst imaginable itch). When condition of pruritus improves, percent change from baseline at Week 12 indicates negative value (i.e. the higher the absolute value is, the more the condition improves).

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

264 participants

Primary outcome timeframe

baseline to Week 12

Results posted on

2022-01-25

Participant Flow

The patients were enrolled at 57 investigational sites in the UK, Germany, Poland, Japan, and the US.

Patient eligibility was assessed during the screening period (Day -28 to Day -8). If all eligibility criteria were met, the patient entered a 7-day run-in period (Day -7 to Day -1) during which all prohibited treatments were discontinued. Baseline assessments were performed until randomization on Day 1.

Participant milestones

Participant milestones
Measure	Placebo The study was undertaken in two parts, Part A and Part B. A Safety Follow-up visit was performed 12 weeks after the last dose of study drug. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received placebo subcutaneously every 4 weeks on Day 1, Week 4 and Week 8. Placebo-to-active period (Part B ) (up to Week 64): Patients randomized to placebo group in Part A were re-randomized to Nemoliozumab groups (0.1 mg/kg, 0.5 mg/kg or 2.0 mg/kg Q4W) in Part B. Nemoliozumab was given subcutaneously every 4 weeks for 52 weeks. Placebo-treated patients in Part A were not re-randomized to Nemoliozumab (2.0 mg/kg) Q8W group in Part B.	Nemoliozumab (0.1 mg/kg) Q4W The study was undertaken in two parts, Part A and Part B. A Safety Follow-up visit was performed 12 weeks after the last dose of study drug. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.1 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8. Active-to-active period (Part B ) (up to Week 64): Patients in the Nemoliozumab (0.1 mg/kg) Q4W group during Part A continuously used the same regimen of Nemoliozumab in Part B. Placebo-to-active period (Part B) (up to Week 64): Patients in the Placebo group during Part A were re-randomized to Nemoliozumab groups (0.1 mg/kg, 0.5 mg/kg or 2.0 mg/kg Q4W) in Part B.	Nemoliozumab (0.5 mg/kg) Q4W The study was undertaken in two parts, Part A and Part B. A Safety Follow-up visit was performed 12 weeks after the last dose of study drug. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.5 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8. Active-to-active period (Part B ) (up to Week 64): Patients in the Nemoliozumab (0.5 mg/kg) Q4W group during Part A continuously used the same regimen of Nemoliozumab in Part B. Placebo-to-active period (Part B) (up to Week 64): Patients in the Placebo group during Part A were re-randomized to Nemoliozumab groups (0.1 mg/kg, 0.5 mg/kg or 2.0 mg/kg Q4W) in Part B.	Nemoliozumab (2.0 mg/kg) Q4W The study was undertaken in two parts, Part A and Part B. A Safety Follow-up visit was performed 12 weeks after the last dose of study drug. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (2.0 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8. Active-to-active period (Part B ) (up to Week 64): Patients in the Nemoliozumab (2.0 mg/kg) Q4W group during Part A continuously used the same regimen of Nemoliozumab in Part B. Placebo-to-active period (Part B) (up to Week 64): Patients in the Placebo group during Part A were re-randomized to Nemoliozumab groups (0.1 mg/kg, 0.5 mg/kg or 2.0 mg/kg Q4W) in Part B.	Nemoliozumab (2.0 mg/kg) Q8W The study was undertaken in two parts, Part A and Part B. A Safety Follow-up visit was performed 12 weeks after the last dose of study drug. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (2.0 mg/kg) subcutaneously every 8 weeks on Day 1 and Week 8. Active-to-active period (Part B ) (up to Week 64): Patients in the Nemoliozumab (2.0 mg/kg) Q8W group during Part A continuously used the same regimen of Nemoliozumab in Part B. Placebo-to-active period (Part B) (up to Week 64): Placebo-treated patients in Part A were not re-randomized to Nemoliozumab (2.0 mg/kg) Q8W group in Part B.
Placebo-controlled (Part A) STARTED	53	53	54	52	52
Placebo-controlled (Part A) COMPLETED	44	44	45	45	38
Placebo-controlled (Part A) NOT COMPLETED	9	9	9	7	14
Active-to-active (Part B) STARTED	0	41	38	39	35
Active-to-active (Part B) COMPLETED	0	31	28	30	19
Active-to-active (Part B) NOT COMPLETED	0	10	10	9	16
Placebo-to-active (Part B) STARTED	0	13	12	13	0
Placebo-to-active (Part B) COMPLETED	0	8	7	8	0
Placebo-to-active (Part B) NOT COMPLETED	0	5	5	5	0

Reasons for withdrawal

Reasons for withdrawal
Measure	Placebo The study was undertaken in two parts, Part A and Part B. A Safety Follow-up visit was performed 12 weeks after the last dose of study drug. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received placebo subcutaneously every 4 weeks on Day 1, Week 4 and Week 8. Placebo-to-active period (Part B ) (up to Week 64): Patients randomized to placebo group in Part A were re-randomized to Nemoliozumab groups (0.1 mg/kg, 0.5 mg/kg or 2.0 mg/kg Q4W) in Part B. Nemoliozumab was given subcutaneously every 4 weeks for 52 weeks. Placebo-treated patients in Part A were not re-randomized to Nemoliozumab (2.0 mg/kg) Q8W group in Part B.	Nemoliozumab (0.1 mg/kg) Q4W The study was undertaken in two parts, Part A and Part B. A Safety Follow-up visit was performed 12 weeks after the last dose of study drug. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.1 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8. Active-to-active period (Part B ) (up to Week 64): Patients in the Nemoliozumab (0.1 mg/kg) Q4W group during Part A continuously used the same regimen of Nemoliozumab in Part B. Placebo-to-active period (Part B) (up to Week 64): Patients in the Placebo group during Part A were re-randomized to Nemoliozumab groups (0.1 mg/kg, 0.5 mg/kg or 2.0 mg/kg Q4W) in Part B.	Nemoliozumab (0.5 mg/kg) Q4W The study was undertaken in two parts, Part A and Part B. A Safety Follow-up visit was performed 12 weeks after the last dose of study drug. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.5 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8. Active-to-active period (Part B ) (up to Week 64): Patients in the Nemoliozumab (0.5 mg/kg) Q4W group during Part A continuously used the same regimen of Nemoliozumab in Part B. Placebo-to-active period (Part B) (up to Week 64): Patients in the Placebo group during Part A were re-randomized to Nemoliozumab groups (0.1 mg/kg, 0.5 mg/kg or 2.0 mg/kg Q4W) in Part B.	Nemoliozumab (2.0 mg/kg) Q4W The study was undertaken in two parts, Part A and Part B. A Safety Follow-up visit was performed 12 weeks after the last dose of study drug. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (2.0 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8. Active-to-active period (Part B ) (up to Week 64): Patients in the Nemoliozumab (2.0 mg/kg) Q4W group during Part A continuously used the same regimen of Nemoliozumab in Part B. Placebo-to-active period (Part B) (up to Week 64): Patients in the Placebo group during Part A were re-randomized to Nemoliozumab groups (0.1 mg/kg, 0.5 mg/kg or 2.0 mg/kg Q4W) in Part B.	Nemoliozumab (2.0 mg/kg) Q8W The study was undertaken in two parts, Part A and Part B. A Safety Follow-up visit was performed 12 weeks after the last dose of study drug. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (2.0 mg/kg) subcutaneously every 8 weeks on Day 1 and Week 8. Active-to-active period (Part B ) (up to Week 64): Patients in the Nemoliozumab (2.0 mg/kg) Q8W group during Part A continuously used the same regimen of Nemoliozumab in Part B. Placebo-to-active period (Part B) (up to Week 64): Placebo-treated patients in Part A were not re-randomized to Nemoliozumab (2.0 mg/kg) Q8W group in Part B.
Placebo-controlled (Part A) Adverse Event	1	5	2	2	4
Placebo-controlled (Part A) Lack of Efficacy	3	1	1	2	1
Placebo-controlled (Part A) Withdrawal by Subject	5	2	6	2	7
Placebo-controlled (Part A) Lost to Follow-up	0	1	0	1	0
Placebo-controlled (Part A) Others (not classified above reasons)	0	0	0	0	2
Active-to-active (Part B) Adverse Event	0	2	0	1	3
Active-to-active (Part B) Lack of Efficacy	0	3	2	0	4
Active-to-active (Part B) Pregnancy	0	0	0	0	1
Active-to-active (Part B) Physician Decision	0	0	1	1	0
Active-to-active (Part B) Withdrawal by Subject	0	4	7	6	6
Active-to-active (Part B) Lost to Follow-up	0	0	0	0	1
Active-to-active (Part B) Others (not classified above reasons)	0	1	0	1	1
Placebo-to-active (Part B) Adverse Event	0	1	0	1	0
Placebo-to-active (Part B) Lack of Efficacy	0	0	0	1	0
Placebo-to-active (Part B) Protocol Violation	0	0	1	0	0
Placebo-to-active (Part B) Withdrawal by Subject	0	3	4	3	0
Placebo-to-active (Part B) Lost to Follow-up	0	1	0	0	0

Baseline Characteristics

A Phase 2 Study of CIM331 for Atopic Dermatitis Patients

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Placebo (Part A) n=46 Participants Data from patients randomized to this group in Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received placebo subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (0.1 mg/kg) Q4W (Part A) n=46 Participants Data from patients randomized to this group in Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.1 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (0.5 mg/kg) Q4W (Part A) n=45 Participants Data from patients randomized to this group in Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.5 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (2.0 mg/kg) Q4W (Part A) n=47 Participants Data from patients randomized to this group in Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (2.0 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (2.0 mg/kg) Q8W (Part A) n=45 Participants Data from patients randomized to this group in Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (2.0 mg/kg) subcutaneously every 8 weeks on Day 1 and Week 8.	Total n=229 Participants Total of all reporting groups
Age, Continuous	35.7 years STANDARD_DEVIATION 13.3 • n=5 Participants	33.9 years STANDARD_DEVIATION 10.2 • n=7 Participants	33.0 years STANDARD_DEVIATION 11.5 • n=5 Participants	33.7 years STANDARD_DEVIATION 12.2 • n=4 Participants	34.6 years STANDARD_DEVIATION 13.3 • n=21 Participants	34.2 years STANDARD_DEVIATION 12.1 • n=8 Participants
Age, Customized Age Category · < 20 years	4 Participants n=5 Participants	0 Participants n=7 Participants	3 Participants n=5 Participants	1 Participants n=4 Participants	1 Participants n=21 Participants	9 Participants n=8 Participants
Age, Customized Age Category · 20 -< 30 years	14 Participants n=5 Participants	21 Participants n=7 Participants	22 Participants n=5 Participants	20 Participants n=4 Participants	21 Participants n=21 Participants	98 Participants n=8 Participants
Age, Customized Age Category · 30 -< 40 years	10 Participants n=5 Participants	15 Participants n=7 Participants	7 Participants n=5 Participants	13 Participants n=4 Participants	7 Participants n=21 Participants	52 Participants n=8 Participants
Age, Customized Age Category · 40 -< 50 years	8 Participants n=5 Participants	4 Participants n=7 Participants	6 Participants n=5 Participants	7 Participants n=4 Participants	7 Participants n=21 Participants	32 Participants n=8 Participants
Age, Customized Age Category · 50 -< 60 years	8 Participants n=5 Participants	6 Participants n=7 Participants	7 Participants n=5 Participants	4 Participants n=4 Participants	7 Participants n=21 Participants	32 Participants n=8 Participants
Age, Customized Age Category · > 60 years	2 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	2 Participants n=4 Participants	2 Participants n=21 Participants	6 Participants n=8 Participants
Sex: Female, Male Female	23 Participants n=5 Participants	21 Participants n=7 Participants	27 Participants n=5 Participants	18 Participants n=4 Participants	21 Participants n=21 Participants	110 Participants n=8 Participants
Sex: Female, Male Male	23 Participants n=5 Participants	25 Participants n=7 Participants	18 Participants n=5 Participants	29 Participants n=4 Participants	24 Participants n=21 Participants	119 Participants n=8 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	1 Participants n=21 Participants	3 Participants n=8 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	45 Participants n=5 Participants	45 Participants n=7 Participants	44 Participants n=5 Participants	45 Participants n=4 Participants	44 Participants n=21 Participants	223 Participants n=8 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	1 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	3 Participants n=8 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants
Race (NIH/OMB) Asian	13 Participants n=5 Participants	17 Participants n=7 Participants	11 Participants n=5 Participants	15 Participants n=4 Participants	14 Participants n=21 Participants	70 Participants n=8 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants
Race (NIH/OMB) Black or African American	1 Participants n=5 Participants	3 Participants n=7 Participants	6 Participants n=5 Participants	1 Participants n=4 Participants	4 Participants n=21 Participants	15 Participants n=8 Participants
Race (NIH/OMB) White	32 Participants n=5 Participants	26 Participants n=7 Participants	27 Participants n=5 Participants	30 Participants n=4 Participants	27 Participants n=21 Participants	142 Participants n=8 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants
Height	167.81 Centimetre STANDARD_DEVIATION 8.84 • n=5 Participants	170.19 Centimetre STANDARD_DEVIATION 10.52 • n=7 Participants	167.41 Centimetre STANDARD_DEVIATION 9.44 • n=5 Participants	170.04 Centimetre STANDARD_DEVIATION 8.84 • n=4 Participants	167.58 Centimetre STANDARD_DEVIATION 9.63 • n=21 Participants	168.62 Centimetre STANDARD_DEVIATION 9.47 • n=8 Participants
Weight	74.20 Kilogram STANDARD_DEVIATION 21.60 • n=5 Participants	76.01 Kilogram STANDARD_DEVIATION 22.90 • n=7 Participants	73.40 Kilogram STANDARD_DEVIATION 19.98 • n=5 Participants	72.51 Kilogram STANDARD_DEVIATION 16.04 • n=4 Participants	72.63 Kilogram STANDARD_DEVIATION 20.96 • n=21 Participants	73.75 Kilogram STANDARD_DEVIATION 20.27 • n=8 Participants
Weight Category < 60 kg	11 Participants n=5 Participants	12 Participants n=7 Participants	15 Participants n=5 Participants	11 Participants n=4 Participants	15 Participants n=21 Participants	64 Participants n=8 Participants
Weight Category >- 60 kg	35 Participants n=5 Participants	34 Participants n=7 Participants	30 Participants n=5 Participants	36 Participants n=4 Participants	30 Participants n=21 Participants	165 Participants n=8 Participants
Body mass index	26.20 Kilogram per square metre STANDARD_DEVIATION 6.81 • n=5 Participants	25.92 Kilogram per square metre STANDARD_DEVIATION 6.41 • n=7 Participants	26.10 Kilogram per square metre STANDARD_DEVIATION 6.66 • n=5 Participants	25.08 Kilogram per square metre STANDARD_DEVIATION 5.26 • n=4 Participants	25.71 Kilogram per square metre STANDARD_DEVIATION 6.47 • n=21 Participants	25.80 Kilogram per square metre STANDARD_DEVIATION 6.30 • n=8 Participants
Body Mass Index Category < 25 kg/m^2	27 Participants n=5 Participants	26 Participants n=7 Participants	23 Participants n=5 Participants	28 Participants n=4 Participants	23 Participants n=21 Participants	127 Participants n=8 Participants
Body Mass Index Category >- 25 kg/m^2	19 Participants n=5 Participants	20 Participants n=7 Participants	22 Participants n=5 Participants	19 Participants n=4 Participants	22 Participants n=21 Participants	102 Participants n=8 Participants

PRIMARY outcome

Timeframe: baseline to Week 12

Population: The per-protocol (PP) population in Part A was used for the analysis. The PP population was defined as a subset of the intent to treat (ITT) population excluding some of the major protocol violators, patients who were withdrawn before being evaluated for pruritus VAS at Week 8, or those who withdrew prior to receiving two or more study drug administrations. Patients who received the wrong study drug were also excluded from the PP population.

Outcome measures

Outcome measures
Measure	Placebo (Part A) n=43 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received placebo subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (0.1 mg/kg) Q4W (Part A) n=44 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.1 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (0.5 mg/kg) Q4W (Part A) n=43 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.5 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (2.0 mg/kg) Q4W (Part A) n=46 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (2.0 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.
Percent Changes From Baseline in Pruritus Visual Analogue Scale (VAS) at Week 12	-20.07 percentage change Interval -29.94 to -10.21	-41.46 percentage change Interval -51.21 to -31.71	-61.24 percentage change Interval -71.13 to -51.35	-60.46 percentage change Interval -69.98 to -50.95

SECONDARY outcome

Timeframe: baseline to Week 12 (Part A)

Population: The per-protocol (PP) population in Part A was used for the analysis. The PP population was defined as a subset of the ITT population excluding some of the major protocol violators , patients who were withdrawn before being evaluated for pruritus VAS at Week 8, or those who withdrew prior to receiving two or more study drug administrations. Patients who received the wrong study drug were also excluded from the PP population.

EASI score was used to measure the severity and extent of atopic eczema. The intensity of a representative area of eczema and the approximate percentage affected by eczema were calculated for each of the four body regions: head and neck, upper limbs, trunk, and lower limbs. The sum of the above 4 body region scores was calculated and should be 0 (none) to 72 (severest). When the condition of eczema improves, the percent change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).

Outcome measures

Outcome measures
Measure	Placebo (Part A) n=46 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received placebo subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (0.1 mg/kg) Q4W (Part A) n=46 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.1 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (0.5 mg/kg) Q4W (Part A) n=45 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.5 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (2.0 mg/kg) Q4W (Part A) n=47 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (2.0 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.
Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A, PP Population) Week 4	-12.12 percentage change from baseline Standard Deviation 40.00	-26.89 percentage change from baseline Standard Deviation 44.48	-35.70 percentage change from baseline Standard Deviation 44.29	-33.86 percentage change from baseline Standard Deviation 34.14
Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A, PP Population) Week 8	-21.82 percentage change from baseline Standard Deviation 47.00	-25.17 percentage change from baseline Standard Deviation 51.79	-46.20 percentage change from baseline Standard Deviation 42.62	-39.89 percentage change from baseline Standard Deviation 34.43
Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A, PP Population) Week 12	-20.89 percentage change from baseline Standard Deviation 47.63	-27.88 percentage change from baseline Standard Deviation 50.50	-44.57 percentage change from baseline Standard Deviation 48.21	-40.29 percentage change from baseline Standard Deviation 37.70

SECONDARY outcome

Timeframe: baseline to Week 12 (Part A), up to Week 64 (Part B)

Population: The intent to treat (ITT) Long population was used for the analysis. The ITT Long population included patients randomized to Nemoliozumab treatment groups in Part A and patients re-randomized from the placebo group to Nemoliozumab treatment groups, providing they received at least one dose of Nemoliozumab and providing the results of at least one post-dose efficacy assessment was available.

Outcome measures

Outcome measures
Measure	Placebo (Part A) n=53 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received placebo subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (0.1 mg/kg) Q4W (Part A) n=54 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.1 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (0.5 mg/kg) Q4W (Part A) n=52 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.5 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (2.0 mg/kg) Q4W (Part A) n=52 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (2.0 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.
Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A + Part B, ITT Long Population) Week 4	-25.47 percentage change from baseline Standard Deviation 42.41	-32.11 percentage change from baseline Standard Deviation 43.70	-32.48 percentage change from baseline Standard Deviation 34.02	-25.43 percentage change from baseline Standard Deviation 35.58
Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A + Part B, ITT Long Population) Week 8	-25.13 percentage change from baseline Standard Deviation 49.82	-47.86 percentage change from baseline Standard Deviation 41.38	-41.02 percentage change from baseline Standard Deviation 36.50	-33.35 percentage change from baseline Standard Deviation 38.00
Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A + Part B, ITT Long Population) Week 12	-35.11 percentage change from baseline Standard Deviation 47.92	-47.75 percentage change from baseline Standard Deviation 45.41	-46.78 percentage change from baseline Standard Deviation 35.15	-42.12 percentage change from baseline Standard Deviation 40.82
Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A + Part B, ITT Long Population) Week 24	-55.83 percentage change from baseline Standard Deviation 42.25	-62.71 percentage change from baseline Standard Deviation 44.37	-56.26 percentage change from baseline Standard Deviation 34.68	-51.01 percentage change from baseline Standard Deviation 37.07
Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A + Part B, ITT Long Population) Week 48	-69.90 percentage change from baseline Standard Deviation 28.17	-71.16 percentage change from baseline Standard Deviation 43.31	-61.14 percentage change from baseline Standard Deviation 44.43	-74.29 percentage change from baseline Standard Deviation 33.97
Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A + Part B, ITT Long Population) Week 60	-63.11 percentage change from baseline Standard Deviation 41.89	-78.81 percentage change from baseline Standard Deviation 28.82	-70.85 percentage change from baseline Standard Deviation 36.24	-70.87 percentage change from baseline Standard Deviation 32.84
Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A + Part B, ITT Long Population) Week 64	-68.45 percentage change from baseline Standard Deviation 41.62	-75.79 percentage change from baseline Standard Deviation 25.40	-78.91 percentage change from baseline Standard Deviation 24.34	-69.25 percentage change from baseline Standard Deviation 43.96

SECONDARY outcome

Timeframe: baseline to Week 12 (Part A)

SCORAD is a clinical tool used to assess the extent and severity of eczema. Area and intensity, were assessed by the Investigator and subjective symptoms were reported by the patient in order to determine an overall score. The score should be 0 to 103: mild \[\<25\], moderate \[25-50\] or severe \[\>50\]). When the condition of eczema improves, the percent change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).

Outcome measures

Outcome measures
Measure	Placebo (Part A) n=46 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received placebo subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (0.1 mg/kg) Q4W (Part A) n=46 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.1 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (0.5 mg/kg) Q4W (Part A) n=45 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.5 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (2.0 mg/kg) Q4W (Part A) n=47 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (2.0 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.
Changes From Baseline in SCORing Atopic Dermatitis (SCORAD) (Part A, PP Population) Week 4	-6.83 percentage change from baseline Standard Deviation 25.97	-29.31 percentage change from baseline Standard Deviation 23.58	-34.59 percentage change from baseline Standard Deviation 29.36	-29.82 percentage change from baseline Standard Deviation 21.65
Changes From Baseline in SCORing Atopic Dermatitis (SCORAD) (Part A, PP Population) Week 8	-17.29 percentage change from baseline Standard Deviation 30.74	-26.41 percentage change from baseline Standard Deviation 26.60	-36.81 percentage change from baseline Standard Deviation 29.04	-34.72 percentage change from baseline Standard Deviation 24.33
Changes From Baseline in SCORing Atopic Dermatitis (SCORAD) (Part A, PP Population) Week 12	-15.97 percentage change from baseline Standard Deviation 26.99	-27.22 percentage change from baseline Standard Deviation 25.81	-39.49 percentage change from baseline Standard Deviation 32.68	-38.31 percentage change from baseline Standard Deviation 28.85

SECONDARY outcome

Timeframe: baseline to Week 12 (Part A), up to Week 64 (Part B)

Outcome measures

Outcome measures
Measure	Placebo (Part A) n=53 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received placebo subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (0.1 mg/kg) Q4W (Part A) n=54 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.1 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (0.5 mg/kg) Q4W (Part A) n=52 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.5 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (2.0 mg/kg) Q4W (Part A) n=52 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (2.0 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.
Changes From Baseline in SCORing Atopic Dermatitis (SCORAD) (Part A + Part B, ITT Long Population) Week 4	-27.73 percentage change from baseline Standard Deviation 23.92	-30.30 percentage change from baseline Standard Deviation 30.39	-28.20 percentage change from baseline Standard Deviation 22.65	-25.31 percentage change from baseline Standard Deviation 22.68
Changes From Baseline in SCORing Atopic Dermatitis (SCORAD) (Part A + Part B, ITT Long Population) Week 8	-29.05 percentage change from baseline Standard Deviation 27.17	-36.16 percentage change from baseline Standard Deviation 28.60	-37.52 percentage change from baseline Standard Deviation 23.34	-31.81 percentage change from baseline Standard Deviation 28.42
Changes From Baseline in SCORing Atopic Dermatitis (SCORAD) (Part A + Part B, ITT Long Population) Week 12	-36.35 percentage change from baseline Standard Deviation 22.24	-42.22 percentage change from baseline Standard Deviation 30.72	-42.60 percentage change from baseline Standard Deviation 27.12	-41.85 percentage change from baseline Standard Deviation 20.79
Changes From Baseline in SCORing Atopic Dermatitis (SCORAD) (Part A + Part B, ITT Long Population) Week 24	-48.73 percentage change from baseline Standard Deviation 27.64	-58.15 percentage change from baseline Standard Deviation 28.15	-52.00 percentage change from baseline Standard Deviation 24.97	-49.97 percentage change from baseline Standard Deviation 24.99
Changes From Baseline in SCORing Atopic Dermatitis (SCORAD) (Part A + Part B, ITT Long Population) Week 48	-55.82 percentage change from baseline Standard Deviation 24.21	-59.20 percentage change from baseline Standard Deviation 28.61	-53.82 percentage change from baseline Standard Deviation 29.98	-66.15 percentage change from baseline Standard Deviation 24.43
Changes From Baseline in SCORing Atopic Dermatitis (SCORAD) (Part A + Part B, ITT Long Population) Week 60	-55.08 percentage change from baseline Standard Deviation 24.22	-64.02 percentage change from baseline Standard Deviation 24.24	-63.26 percentage change from baseline Standard Deviation 25.04	-61.03 percentage change from baseline Standard Deviation 24.27
Changes From Baseline in SCORing Atopic Dermatitis (SCORAD) (Part A + Part B, ITT Long Population) Week 64	-56.55 percentage change from baseline Standard Deviation 28.25	-64.02 percentage change from baseline Standard Deviation 27.72	-66.61 percentage change from baseline Standard Deviation 19.90	-63.07 percentage change from baseline Standard Deviation 27.96

SECONDARY outcome

Timeframe: baseline to Week 12 (Part A)

The sIGA consisted of a 6-point severity scale from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease and 5 = very severe disease). The sIGA assessed clinical characteristics of erythema, infiltration, papulation, oozing and crusting for the overall severity assessment at the time of evaluation. When the skin condition improves, the change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).

Outcome measures

Outcome measures
Measure	Placebo (Part A) n=46 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received placebo subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (0.1 mg/kg) Q4W (Part A) n=46 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.1 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (0.5 mg/kg) Q4W (Part A) n=45 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.5 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (2.0 mg/kg) Q4W (Part A) n=47 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (2.0 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.
Changes From Baseline in Static Investigator's Global Assessment (sIGA) (Part A, PP Population) Week 4	-0.2 change from baseline Standard Deviation 0.8	-0.8 change from baseline Standard Deviation 0.9	-0.9 change from baseline Standard Deviation 0.9	-0.6 change from baseline Standard Deviation 0.9
Changes From Baseline in Static Investigator's Global Assessment (sIGA) (Part A, PP Population) Week 8	-0.5 change from baseline Standard Deviation 1.2	-0.7 change from baseline Standard Deviation 1.0	-1.0 change from baseline Standard Deviation 1.2	-0.8 change from baseline Standard Deviation 1.0
Changes From Baseline in Static Investigator's Global Assessment (sIGA) (Part A, PP Population) Week 12	-0.3 change from baseline Standard Deviation 1.0	-0.7 change from baseline Standard Deviation 1.0	-1.0 change from baseline Standard Deviation 1.1	-0.8 change from baseline Standard Deviation 1.1

SECONDARY outcome

Timeframe: baseline to Week 12 (Part A), up to Week 64 (Part B)

Outcome measures

Outcome measures
Measure	Placebo (Part A) n=53 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received placebo subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (0.1 mg/kg) Q4W (Part A) n=54 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.1 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (0.5 mg/kg) Q4W (Part A) n=52 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.5 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (2.0 mg/kg) Q4W (Part A) n=52 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (2.0 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.
Changes From Baseline in Static Investigator's Global Assessment (sIGA) (Part A + Part B, ITT Long Population) Week 48	-1.7 change from baseline Standard Deviation 1.2	-1.8 change from baseline Standard Deviation 0.8	-1.4 change from baseline Standard Deviation 1.2	-2.0 change from baseline Standard Deviation 1.2
Changes From Baseline in Static Investigator's Global Assessment (sIGA) (Part A + Part B, ITT Long Population) Week 60	-1.9 change from baseline Standard Deviation 1.0	-2.0 change from baseline Standard Deviation 0.9	-1.7 change from baseline Standard Deviation 1.1	-1.7 change from baseline Standard Deviation 1.1
Changes From Baseline in Static Investigator's Global Assessment (sIGA) (Part A + Part B, ITT Long Population) Week 64	-1.9 change from baseline Standard Deviation 1.1	-1.9 change from baseline Standard Deviation 0.9	-1.7 change from baseline Standard Deviation 1.0	-1.8 change from baseline Standard Deviation 1.3
Changes From Baseline in Static Investigator's Global Assessment (sIGA) (Part A + Part B, ITT Long Population) Week 4	-0.7 change from baseline Standard Deviation 0.9	-0.8 change from baseline Standard Deviation 0.9	-0.6 change from baseline Standard Deviation 0.9	-0.4 change from baseline Standard Deviation 0.8
Changes From Baseline in Static Investigator's Global Assessment (sIGA) (Part A + Part B, ITT Long Population) Week 8	-0.8 change from baseline Standard Deviation 1.0	-1.0 change from baseline Standard Deviation 1.2	-0.9 change from baseline Standard Deviation 0.9	-0.5 change from baseline Standard Deviation 0.9
Changes From Baseline in Static Investigator's Global Assessment (sIGA) (Part A + Part B, ITT Long Population) Week 12	-0.9 change from baseline Standard Deviation 0.9	-1.1 change from baseline Standard Deviation 1.1	-0.9 change from baseline Standard Deviation 1.0	-0.9 change from baseline Standard Deviation 0.8
Changes From Baseline in Static Investigator's Global Assessment (sIGA) (Part A + Part B, ITT Long Population) Week 24	-1.5 change from baseline Standard Deviation 1.1	-1.7 change from baseline Standard Deviation 1.0	-1.2 change from baseline Standard Deviation 1.0	-1.2 change from baseline Standard Deviation 1.1

SECONDARY outcome

Timeframe: baseline to Week 12 (Part A)

The total BSA affected by AD was assessed as part of SCORAD. The BSA is a measure of the severity of AD, and it is considered to be severe when the rash with strong inflammation is 10 % or more of the total BSA. When the BSA of AD involvement decreases, the change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the BSA of AD involvement decreases).

Outcome measures

Outcome measures
Measure	Placebo (Part A) n=46 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received placebo subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (0.1 mg/kg) Q4W (Part A) n=46 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.1 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (0.5 mg/kg) Q4W (Part A) n=45 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.5 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (2.0 mg/kg) Q4W (Part A) n=47 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (2.0 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.
Changes From Baseline in Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement (Part A, PP Population) Week 4	-7.48 percentage change from baseline Standard Deviation 37.14	-12.11 percentage change from baseline Standard Deviation 43.69	-23.49 percentage change from baseline Standard Deviation 40.93	-18.44 percentage change from baseline Standard Deviation 35.47
Changes From Baseline in Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement (Part A, PP Population) Week 8	-14.44 percentage change from baseline Standard Deviation 49.29	-14.90 percentage change from baseline Standard Deviation 45.84	-27.23 percentage change from baseline Standard Deviation 47.17	-22.99 percentage change from baseline Standard Deviation 38.58
Changes From Baseline in Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement (Part A, PP Population) Week 12	-13.29 percentage change from baseline Standard Deviation 49.87	-17.54 percentage change from baseline Standard Deviation 47.16	-19.68 percentage change from baseline Standard Deviation 67.49	-24.36 percentage change from baseline Standard Deviation 41.84

SECONDARY outcome

Timeframe: baseline to Week 12 (Part A), up to Week 64 (Part B)

Outcome measures

Outcome measures
Measure	Placebo (Part A) n=53 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received placebo subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (0.1 mg/kg) Q4W (Part A) n=54 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.1 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (0.5 mg/kg) Q4W (Part A) n=52 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.5 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (2.0 mg/kg) Q4W (Part A) n=52 Participants Data from Part A were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (2.0 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.
Changes From Baseline in Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement (Part A + Part B, ITT Long Population) Week 60	-60.41 percentage change from baseline Standard Deviation 37.00	-70.44 percentage change from baseline Standard Deviation 35.81	-60.99 percentage change from baseline Standard Deviation 48.00	-58.38 percentage change from baseline Standard Deviation 44.97
Changes From Baseline in Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement (Part A + Part B, ITT Long Population) Week 48	-65.21 percentage change from baseline Standard Deviation 32.63	-69.20 percentage change from baseline Standard Deviation 39.95	-49.66 percentage change from baseline Standard Deviation 44.18	-59.97 percentage change from baseline Standard Deviation 50.32
Changes From Baseline in Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement (Part A + Part B, ITT Long Population) Week 12	-24.53 percentage change from baseline Standard Deviation 49.77	-25.31 percentage change from baseline Standard Deviation 63.43	-25.91 percentage change from baseline Standard Deviation 44.40	-18.56 percentage change from baseline Standard Deviation 52.30
Changes From Baseline in Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement (Part A + Part B, ITT Long Population) Week 64	-62.54 percentage change from baseline Standard Deviation 40.92	-66.01 percentage change from baseline Standard Deviation 36.38	-63.35 percentage change from baseline Standard Deviation 40.37	-60.54 percentage change from baseline Standard Deviation 55.96
Changes From Baseline in Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement (Part A + Part B, ITT Long Population) Week 24	-48.13 percentage change from baseline Standard Deviation 39.07	-51.41 percentage change from baseline Standard Deviation 44.10	-40.53 percentage change from baseline Standard Deviation 42.94	-36.91 percentage change from baseline Standard Deviation 40.99
Changes From Baseline in Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement (Part A + Part B, ITT Long Population) Week 4	-10.12 percentage change from baseline Standard Deviation 45.56	-23.28 percentage change from baseline Standard Deviation 38.96	-17.98 percentage change from baseline Standard Deviation 35.12	-2.79 percentage change from baseline Standard Deviation 54.12
Changes From Baseline in Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement (Part A + Part B, ITT Long Population) Week 8	-18.08 percentage change from baseline Standard Deviation 45.82	-29.58 percentage change from baseline Standard Deviation 47.13	-24.64 percentage change from baseline Standard Deviation 37.49	-6.66 percentage change from baseline Standard Deviation 59.40

Adverse Events

Placebo (Part A)

Serious events: 1 serious events

Other events: 27 other events

Deaths: 0 deaths

Nemoliozumab (0.1 mg/kg) Q4W (Part A)

Serious events: 1 serious events

Other events: 29 other events

Deaths: 0 deaths

Nemoliozumab (0.5 mg/kg) Q4W (Part A)

Serious events: 0 serious events

Other events: 23 other events

Deaths: 0 deaths

Nemoliozumab (2.0 mg/kg) Q4W (Part A)

Serious events: 3 serious events

Other events: 27 other events

Deaths: 0 deaths

Nemoliozumab (2.0 mg/kg) Q8W (Part A)

Serious events: 5 serious events

Other events: 25 other events

Deaths: 0 deaths

Nemoliozumab (0.1 mg/kg) Q4W (Part A + Part B)

Serious events: 3 serious events

Other events: 37 other events

Deaths: 0 deaths

Nemoliozumab (0.5 mg/kg) Q4W (Part A + Part B)

Serious events: 3 serious events

Other events: 35 other events

Deaths: 0 deaths

Nemoliozumab (2.0 mg/kg) Q4W (Part A + Part B)

Serious events: 4 serious events

Other events: 33 other events

Deaths: 0 deaths

Nemoliozumab (2.0 mg/kg) Q8W (Part A + Part B)

Serious events: 9 serious events

Other events: 35 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Placebo (Part A) n=53 participants at risk Data from Part A and Safety Follow-up period were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received placebo subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (0.1 mg/kg) Q4W (Part A) n=53 participants at risk Data from Part A and Safety Follow-up period were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.1 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (0.5 mg/kg) Q4W (Part A) n=54 participants at risk Data from Part A and Safety Follow-up period were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.5 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (2.0 mg/kg) Q4W (Part A) n=52 participants at risk Data from Part A and Safety Follow-up period were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (2.0 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (2.0 mg/kg) Q8W (Part A) n=52 participants at risk Data from Part A and Safety Follow-up period were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (2.0 mg/kg) subcutaneously every 8 weeks on Day 1 and Week 8.	Nemoliozumab (0.1 mg/kg) Q4W (Part A + Part B) n=53 participants at risk Data from Part A, Part B and Safety Follow-up period were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.1 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8. Active-to-active period (Part B) (up to Week 64): Patients in the Nemoliozumab (0.1 mg/kg) Q4W group during Part A continuously used the same regimen of Nemoliozumab in Part B.	Nemoliozumab (0.5 mg/kg) Q4W (Part A + Part B) n=54 participants at risk Data from Part A, Part B and Safety Follow-up period were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.5 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8. Active-to-active period (Part B) (up to Week 64): Patients in the Nemoliozumab (0.5 mg/kg) Q4W group during Part A continuously used the same regimen of Nemoliozumab in Part B.	Nemoliozumab (2.0 mg/kg) Q4W (Part A + Part B) n=52 participants at risk Data from Part A, Part B and Safety Follow-up period were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (2.0 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8. Active-to-active period (Part B) (up to Week 64): Patients in the Nemoliozumab (2.0 mg/kg) Q4W group during Part A continuously used the same regimen of Nemoliozumab in Part B.	Nemoliozumab (2.0 mg/kg) Q8W (Part A + Part B) n=52 participants at risk Data from Part A, Part B and Safety Follow-up period were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (2.0 mg/kg) subcutaneously every 8 weeks on Day 1 and Week 8. Active-to-active period (Part B) (up to Week 64): Patients in the Nemoliozumab (2.0 mg/kg) Q8W group during Part A continuously used the same regimen of Nemoliozumab in Part B.
Skin and subcutaneous tissue disorders Dermatitis atopic	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	3.8% 2/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	3.8% 2/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	3.8% 2/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Skin and subcutaneous tissue disorders Dermatitis exfoliative	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Skin and subcutaneous tissue disorders Rash	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Skin and subcutaneous tissue disorders Urticaria	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Infections and infestations Herpes simplex	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Infections and infestations Herpes zoster	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Infections and infestations Pyelonephritis	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Infections and infestations Pyoderma	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Infections and infestations Skin infection	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Infections and infestations Infection	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	3.8% 2/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	3.8% 2/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Cardiac disorders Atrial fibrillation	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Cardiac disorders Coronary artery stenosis	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Nervous system disorders Grand mal convulsion	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Nervous system disorders Parkinson's disease	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Blood and lymphatic system disorders Lymphadenopathy	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Eye disorders Cataract	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Eye disorders Retinal detachment	1.9% 1/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Hepatobiliary disorders Non-alcoholic steatohepatitis	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Injury, poisoning and procedural complications Joint dislocation	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Injury, poisoning and procedural complications Upper limb fracture	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.

Other adverse events

Other adverse events
Measure	Placebo (Part A) n=53 participants at risk Data from Part A and Safety Follow-up period were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received placebo subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (0.1 mg/kg) Q4W (Part A) n=53 participants at risk Data from Part A and Safety Follow-up period were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.1 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (0.5 mg/kg) Q4W (Part A) n=54 participants at risk Data from Part A and Safety Follow-up period were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.5 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (2.0 mg/kg) Q4W (Part A) n=52 participants at risk Data from Part A and Safety Follow-up period were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (2.0 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8.	Nemoliozumab (2.0 mg/kg) Q8W (Part A) n=52 participants at risk Data from Part A and Safety Follow-up period were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (2.0 mg/kg) subcutaneously every 8 weeks on Day 1 and Week 8.	Nemoliozumab (0.1 mg/kg) Q4W (Part A + Part B) n=53 participants at risk Data from Part A, Part B and Safety Follow-up period were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.1 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8. Active-to-active period (Part B) (up to Week 64): Patients in the Nemoliozumab (0.1 mg/kg) Q4W group during Part A continuously used the same regimen of Nemoliozumab in Part B.	Nemoliozumab (0.5 mg/kg) Q4W (Part A + Part B) n=54 participants at risk Data from Part A, Part B and Safety Follow-up period were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (0.5 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8. Active-to-active period (Part B) (up to Week 64): Patients in the Nemoliozumab (0.5 mg/kg) Q4W group during Part A continuously used the same regimen of Nemoliozumab in Part B.	Nemoliozumab (2.0 mg/kg) Q4W (Part A + Part B) n=52 participants at risk Data from Part A, Part B and Safety Follow-up period were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (2.0 mg/kg) subcutaneously every 4 weeks on Day 1, Week 4 and Week 8. Active-to-active period (Part B) (up to Week 64): Patients in the Nemoliozumab (2.0 mg/kg) Q4W group during Part A continuously used the same regimen of Nemoliozumab in Part B.	Nemoliozumab (2.0 mg/kg) Q8W (Part A + Part B) n=52 participants at risk Data from Part A, Part B and Safety Follow-up period were analyzed. Placebo-controlled period (Part A) (Day 1 to Week 12): Patients randomized to this group received Nemoliozumab (2.0 mg/kg) subcutaneously every 8 weeks on Day 1 and Week 8. Active-to-active period (Part B) (up to Week 64): Patients in the Nemoliozumab (2.0 mg/kg) Q8W group during Part A continuously used the same regimen of Nemoliozumab in Part B.
Infections and infestations Nasopharyngitis	15.1% 8/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	17.0% 9/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	11.1% 6/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	9.6% 5/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	13.5% 7/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	28.3% 15/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	25.9% 14/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	28.8% 15/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	23.1% 12/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Infections and infestations Upper respiratory tract infection	11.3% 6/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	7.5% 4/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	7.7% 4/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	9.6% 5/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	11.3% 6/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	5.6% 3/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	9.6% 5/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	9.6% 5/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Infections and infestations Impetigo	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	7.5% 4/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	11.3% 6/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	5.6% 3/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	5.8% 3/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Infections and infestations Influenza	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	9.4% 5/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	3.8% 2/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Infections and infestations Pharyngitis	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	5.6% 3/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	5.8% 3/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Infections and infestations Bronchitis	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	5.7% 3/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	3.7% 2/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	3.8% 2/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Infections and infestations Cystitis	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	5.6% 3/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Infections and infestations Sinusitis	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	5.6% 3/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Infections and infestations Folliculitis	5.7% 3/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	5.8% 3/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Skin and subcutaneous tissue disorders Dermatitis atopic	13.2% 7/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	20.8% 11/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	18.5% 10/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	17.3% 9/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	17.3% 9/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	28.3% 15/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	22.2% 12/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	23.1% 12/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	17.3% 9/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Skin and subcutaneous tissue disorders Urticaria	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	5.6% 3/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
General disorders Oedema peripheral	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	3.8% 2/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	5.6% 3/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	9.6% 5/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	3.8% 2/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	3.8% 2/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	5.6% 3/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	11.5% 6/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	3.8% 2/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Investigations Blood creatine phosphokinase increased	5.7% 3/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	3.8% 2/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	3.7% 2/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	7.7% 4/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	5.8% 3/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	9.4% 5/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	5.6% 3/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	17.3% 9/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	11.5% 6/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Nervous system disorders Headache	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	5.7% 3/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	3.7% 2/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	5.8% 3/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	5.7% 3/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	11.1% 6/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	9.6% 5/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	3.8% 2/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Nervous system disorders Dizziness	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	5.7% 3/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	3.8% 2/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	3.8% 2/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	5.6% 3/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Respiratory, thoracic and mediastinal disorders Asthma	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	5.7% 3/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	0.00% 0/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	3.7% 2/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	5.8% 3/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	3.8% 2/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.
Blood and lymphatic system disorders Lymphadenopathy	5.7% 3/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	3.8% 2/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	5.7% 3/53 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/54 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	1.9% 1/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.	3.8% 2/52 • baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period The Investigator is responsible for ensuring that all adverse events are recorded on the Adverse Event eCRF and reported to the Sponsor. For each adverse event recorded on the Adverse Event eCRF, the Investigator will make an assessment of seriousness, severity, and causality. Note: The Safety population was used for the analysis. The Safety population included all patients who received at least one dose of Nemoliozumab.

Additional Information

Clinical trials information

Chugai Pharmaceutical

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Restriction type: OTHER